Valuation : Mesoblast Limited

Market Cap 2.88B 2.08B 1.79B 1.68B 1.53B 2.87B 198B 19.96B 7.71B 101B 7.81B 7.64B 319B P/E 2027 *
-154x
P/E 2028 * 9.97x
Enterprise Value 2.98B 2.15B 1.85B 1.74B 1.59B 2.97B 205B 20.64B 7.98B 104B 8.07B 7.89B 330B EV / Sales 2027 *
11.3x
EV / Sales 2028 * 4.47x
Free-Float
63.68%
Yield 2027 *
-
Yield 2028 * -
1 day-3.06%
1 week-5.13%
Current month-5.93%
1 month-0.45%
3 months+8.29%
6 months-3.48%
Current year-18.38%
1 week 2.2
Extreme 2.2
2.44
1 month 2.19
Extreme 2.19
2.58
Current year 1.88
Extreme 1.88
3.31
1 year 1.88
Extreme 1.88
3.31
3 years 0.26
Extreme 0.255
3.37
5 years 0.26
Extreme 0.255
3.37
10 years 0.26
Extreme 0.255
5.7
Manager TitleAgeSince
Chief Executive Officer 69 2011-03-22
Director of Finance/CFO 59 2025-11-16
Chief Tech/Sci/R&D Officer - 2026-03-10
Director TitleAgeSince
Director/Board Member 69 2006-12-31
Director/Board Member 75 2013-04-14
Director/Board Member 78 2014-03-05
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 Free

Director

875,000 0.0674%
7/17/26 Exercice

Founder

1,885,334 0.1456%
7/17/26 Exercice

Founder

-1,885,334 0.1456%
Change 5-day change 1-year change 3-year change Capi.($)
-3.06%-5.13%+0.45%+382.61% 2.15B
-3.24%-6.89%-5.65%+11.20% 48.01B
+0.17%-1.04%+405.80%+546.58% 44.44B
-0.86%-0.53%+36.92%+20.35% 42.67B
-0.14%-2.13%+1.31%+82.21% 39.96B
0.00%-2.61%+13.09%+42.33% 32.75B
-3.44%+0.22% - - 17.74B
-0.78%+0.53%+19.14%+116.26% 16.49B
-0.37%-0.87%+10.98%+30.93% 14.38B
-0.86%-1.41%+71.82%+39.36% 13.4B
Average -1.26%-0.69%+61.54%+141.31% 27.2B
Weighted average by Cap. -1.06%-1.11%+83.60%+134.03%

Financials

2027 *2028 *
Net sales 264M 190M 164M 154M 140M 263M 18.09B 1.83B 705M 9.21B 714M 698M 29.19B 556M 401M 345M 325M 296M 554M 38.16B 3.85B 1.49B 19.44B 1.51B 1.47B 61.59B
Net income -19.96M -14.4M -12.39M -11.66M -10.63M -19.89M -1.37B -138M -53.43M -698M -54.06M -52.88M -2.21B 196M 141M 122M 115M 104M 195M 13.46B 1.36B 525M 6.86B 531M 520M 21.73B
Net Debt 97.67M 70.43M 60.6M 57.06M 51.99M 97.28M 6.7B 676M 261M 3.41B 264M 259M 10.82B -398M -287M -247M -233M -212M -397M -27.32B -2.76B -1.07B -13.92B -1.08B -1.05B -44.09B
Logo Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Employees
108
Date Price Change Volume
26-09-09 A$2.220 -3.06% 1,529,366
26-09-08 A$2.290 +2.69% 2,982,986
26-09-07 A$2.230 -6.30% 2,754,848
26-09-04 A$2.380 0.00% 1,294,011
26-09-03 A$2.380 +0.42% 2,074,487
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.220AUD
Average target price
3.905AUD
Spread / Average Target
+75.90%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!